clinical trial · NCT04867616
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
UCB Biopharma SRL·phase2·completed·n = 466
Alzheimer's DiseasePlaceboBepranemab
brief summary
The purpose of the study is to investigate the effect of bepranemab versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's Disease (AD).
started
Jun 9, 2021
primary completion
May 24, 2024
completion
Aug 1, 2025
last updated
Aug 29, 2025
official title
A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer's Disease (AD), Followed by an Open-Label Extension Period
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol